Table 2.
Median MPR with respect to patient characteristics
| Variable | Median MPR | p value |
|---|---|---|
| Sex | ||
| Male | 0.99 (0.00–2.03) | 0.003 |
| Female | 0.98 (0.01–1.55) | |
| Age, yr | ||
| a15–29 | 1.00 (0.01–2.03) | < 0.001 |
| a, b, c > d | ||
| b30–49 | 1.01 (0.00–1.72) | |
| c50–69 | 0.99 (0.01–1.91) | |
| d≥70 | 0.90 (0.01–1.80) | |
| Income | ||
| High | 1.00 (0.00–1.91) | < 0.001 |
| Low | 0.97 (0.01–2.03) | |
| TKI | ||
| aImatinib | 0.98 (0.00–2.03) | < 0.001 |
| a, c > b | ||
| bDasatinib | 0.94 (0.02–1.55) | |
| cNilotinib | 0.98 (0.06–1.69) | |
| dRadotinib | 0.98 (0.22–1.41) | |
| Number of TKIs | ||
| a1 | 1.01 (0.00–2.03) | < 0.001 |
| a > b, c, d | ||
| b2 | 0.91 (0.02–1.54) | |
| c3 | 0.94 (0.10–1.24) | |
| d4 | 0.84 (0.47–1.10) | |
| Concomitant medication | ||
| 0–3 | 0.91 (0.68–1.14) | 0.832 |
| > 4 | 0.90 (0.70–1.10) | |
| Frontline TKI | ||
| Imatinib | 0.98 (0.00–2.03) | < 0.001 |
| Others | 1.02 (0.06–1.69) |
Values are presented as median (range).
MPR, medication possession ratio; TKI, tyrosine kinase inhibitor.